350 related articles for article (PubMed ID: 26596991)
1. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
Torres T; Raposo I; Selores M
Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
3. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
Kim J; Krueger JG
Annu Rev Med; 2017 Jan; 68():255-269. PubMed ID: 27686018
[TBL] [Abstract][Full Text] [Related]
4. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
6. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
7. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
8. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
9. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic implications of IL-17A blockade in psoriasis.
Puig L; Carrascosa JM
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
[No Abstract] [Full Text] [Related]
11. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for psoriasis.
Gottlieb AB
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
[TBL] [Abstract][Full Text] [Related]
13. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
14. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
16. Rationale and early clinical data on IL-17 blockade in psoriasis.
Nwe SM; Champlain AH; Gordon KB
Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
18. A safety evaluation of guselkumab for the treatment of psoriasis.
Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
[No Abstract] [Full Text] [Related]
20. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
